(Clostridioides difficile) is bacteria that causes about 500,000 infections a year in the United States, according to the U.S ...

Zinplava ™ (bezlotoxumab) injection will be discontinued as of January 31, 2025, according to the Food and Drug Administration’s (FDA) drug shortages tracker.

Panelist discusses how recurrent Clostridioides difficile infection results from persistent microbiome disruption, where antibiotic-induced dysbiosis enables bacterial overgrowth and toxin production.

The panelist discusses how early detection of recurrent Clostridioides difficile infections is critical in clinical practice because these infections can rapidly escalate patient morbidity and ...

Goldman Sachs analyst maintains Buy rating on Pfizer with $33 price target. Discusses update on 2nd-gen C. diff vaccine in ...

Xeno Biosciences may have been unable to prove that its drug delivering oxygen to the gastrointestinal tract can induce ...

Clostridioides difficile (C. diff) is a bacterial infection that commonly affects people with ulcerative colitis (UC). It can worsen symptoms and cause complications. It can also trigger a ...

Clostridioides difficile is a gram-positive bacteria that causes disease in persons with dysbiosis of the gut microbiota and has been listed as an urgent threat due to the emergence of resistance.

But in C. difficile cases, the nervous system can have a hyperactive response that becomes part of the problem, and UVA's new ...

LPOXY Therapeutics, Inc. ("LPOXY"), a clinical-stage biopharmaceutical company focused on innovative therapies for infectious ...

Pharmaceuticals is a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for ...